News
24/4/2015

IMIM: A new therapeutic target for a type of colorectal cancer with poor prognosis has been identified

IMIM: A new therapeutic target for a type of colorectal cancer with poor prognosis has been identified


News from IMIM


Researchers at the Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene.

This discovery is an important step in the personalisation of the treatment of colorectal cancer, as the presence of this mutation is associated with an increased resistance compared to standard therapies. Researchers from IDIBELL - the Catalan Institute of Oncology - and the Hospital de Bellvitge also participated.

Colorectal cancer (CRC) is the second leading cause of cancer death in the Western world. Tumours which carry mutations in KRAS genes (40% of CCR) or BRAF genes (between 5 and 15% of these types of cancers) are ineffectively treated and have poor prognosis. "KRAS inhibitor medications are extremely toxic and the use of BRAF inhibitors is limited because tolerance to them can be quickly acquired. This is why identification of new therapeutic targets is vital to improving treatment", explains Dr. Espinosa.

More information:
IMIM news

Reference:
"BRAF induced tumorigenesis is IKKalpha dependent but NF-kB independent". Polo Margalef, Carlota Colomer, Alberto Villanueva, Clara Montagut, Mar Iglesias, Beatriz Bellosillo, Ramón Salazar, María Martínez-Iniesta, Manolis Pasparakis, Anna Bigas, and Lluís Espinosa. Science Signaling